Jung Choi
Director/Board Member chez ANNEXON, INC.
Fortune : - $ au 31/03/2024
Profil
Jung E.
Choi is an Independent Director at Annexon, Inc., and the Chief Business & Strategy Officer at Global Blood Therapeutics, Inc. She is also a Member of Aspen Global Leadership Network.
Previously, she worked as the Head-Corporate Development at Gilead Sciences, Inc., Senior Vice President-Corporate Development at InterMune, Inc., and Chimerix, Inc. She was also an Engagement Manager at McKinsey & Co., Inc. and a Vice President at Bay City Capital LLC.
Ms. Choi holds an undergraduate degree and an MBA from Stanford University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ANNEXON, INC.
-.--% | 08/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Jung Choi
| Sociétés | Poste | Début |
|---|---|---|
| GLOBAL BLOOD THERAPEUTICS, INC. | Corporate Officer/Principal | 01/04/2015 |
| ANNEXON, INC. | Director/Board Member | 01/06/2020 |
| Aspen Global Leadership Network | Corporate Officer/Principal | - |
Anciens postes connus de Jung Choi
| Sociétés | Poste | Fin |
|---|---|---|
| INTERMUNE INC | Corporate Officer/Principal | 01/03/2015 |
| CHIMERIX, INC. | Corporate Officer/Principal | 01/01/2013 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/01/2010 |
Bay City Capital LLC
 Bay City Capital LLC Investment ManagersFinance Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in San Rafael, California. | Corporate Officer/Principal | 01/01/2001 |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/01/1999 |
Formation de Jung Choi
| Stanford University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| CHIMERIX, INC. | Health Technology |
| ANNEXON, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
Bay City Capital LLC
Bay City Capital LLC Investment ManagersFinance Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in San Rafael, California. | Finance |
| Aspen Global Leadership Network | |
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |
